Simulations Plus, Inc. · NASDAQ:SLP

Simulations Plus — FY2023 Earnings Presentation

29 slides from Simulations Plus's earnings presentation, November 2023

  1. Slide 1: Investor Presentation Q4 FY23 Update

    Slide 1: Investor Presentation Q4 FY23 Update

    Investor Presentation NASDAQ : SLP Q4 FY23 Update

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, b

  3. Slide 3: SLP Mission: Improve Health Through Innovative Solutions

    Slide 3: SLP Mission: Improve Health Through Innovative Solutions

    SLP Mission: Improve Health Through Innovative Solutions​ We create value for our customers by accelerating development timelines and reducing the cost of drug development R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives

  4. Slide 4: SLP At a Glance

    Slide 4: SLP At a Glance

    SLP At a Glance Leading Provider of Software and Consulting Services in the Biosimulation Market AI-powered technology solutions optimize the outcomes of drug discovery, development, research, and regulatory submissions processes. Our software-based technology both models and simulates how drugs and

  5. Slide 5: SLP Investment Highlights

    Slide 5: SLP Investment Highlights

    SLP Investment Highlights + + + Industry Leader Biosimulation Compelling in Large and Technology Leader Customer Value Growing Market Leveraging AI Proposition + + + Seasoned Strong Competitive Attractive Management Team Position and Financial Profile and Scientific Barriers Leadership to Entry 5

  6. Slide 6: Drug Discovery & Development

    Slide 6: Drug Discovery & Development

    Drug Discovery & Development​ The Drug Discovery and Development Industry can be broken down into several subindustries, including: 1. TARGET DISCOVERY AND VALIDATION Each of these subindustries represents a different stage of the drug development 2. LEAD COMPOUND IDENTIFICATION AND OPTIMIZATION pro

  7. Slide 7: Drug Development Challenges | SLP Biosimulation Solution

    Slide 7: Drug Development Challenges | SLP Biosimulation Solution

    Drug Development Challenges | SLP Biosimulation Solution​ Our core mission – accelerating the development and delivery of better, safer, and more effective drugs CHALLENGES SIMULATIONS PLUS SOLUTIONS The median cost of developing a new Simulations Plus offers AI-powered technology – drug averages $1

  8. Slide 8: Biosimulation Overview

    Slide 8: Biosimulation Overview

    Biosimulation Overview ​ Biosimulation is software-based technology that models and simulates how drugs and diseases behave in the human body​ Biosimulation combines core principles in biology, chemistry and pharmacology with proprietary mathematical algorithms to predict how biology and drugs inter

  9. Slide 9: Large and Growing Market

    Slide 9: Large and Growing Market

    Large and Growing Market Spending for biosimulation products continues to increase given need to bring drugs to market faster​ + Biosimulation market valued at $2.8B in 2022 and is $200B GLOBAL PHARMA expected to expand at a 16.9% CAGR from 2022 - 2030 AND BIOTECH SPEND (3% CAGR) + Strategy to grow

  10. Slide 10: Secular Trends Driving Sustained Long-Term Growth

    Slide 10: Secular Trends Driving Sustained Long-Term Growth

    Secular Trends Driving Sustained Long-Term Growth​ Drivers include: + Biosimulation taking greater percentage of drug development spend annually + Scarcity of blockbuster drug opportunities drive industry focus to smaller market targets requiring increased development efficiency + Increased scrutiny

  11. Slide 11: End-to-End Solutions Across the Development Life Cycle

    Slide 11: End-to-End Solutions Across the Development Life Cycle

    End-to-End Solutions Across the Development Life Cycle Decrease development uncertainty, cost and time CHEMINFORMATICS PBPK / PBBM/ QST/ QSP PHARMACOMETRICS REGULATORY DRUG A P P R OVA L CONFIDENCE L EVEL OF D RUG A PPROVAL “…combining models and data results in higher confidence in clinical perform

  12. Slide 12: Strong Competitive Position

    Slide 12: Strong Competitive Position

    Strong Competitive Position​ LEADING POSITION IN LARGE, GROWING, FRAGMENTED AND + UNDERPENETRATED MARKET + LARGE, GROWING AND DIVERSE CUSTOMER BASE MOST COMPREHENSIVE AND WIDELY RECOGNIZED TOOLS IN THE + INDUSTRY + 300+ CUSTOMERS ACCUMULATED PUBLIC AND PRIVATE DATA THAT INFORMS OUR + ALGORITHMS AND

  13. Slide 13: Fiscal 2023 Highlights

    Slide 13: Fiscal 2023 Highlights

    Fiscal 2023 Highlights $59.6M $0.49 $0.67 35% $20M Revenue Diluted EPS Adjusted Adj. EBITDA1 as Backlog Diluted EPS1 % of Revenue ▪ Strong revenue and earnings results for fiscal 2023 ▪ Conditions in our market remain similar to what we have seen past several quarters – Small biotech slowdown – Larg

  14. Slide 14: Fiscal 2023 Capital Allocation Strategy

    Slide 14: Fiscal 2023 Capital Allocation Strategy

    Fiscal 2023 Capital Allocation Strategy ▪ Employee Engagement and ▪ Acquisitions (Immunetrics Q4) Development ▪ Investment Opportunities ▪ Product Development ▪ Strategic Partnerships and ▪ ERP Processes and Technology INTERNAL CORPORATE Alliances INVESTMENT DEVELOPMENT ▪ $0.06 per share paid Feb. 6

  15. Slide 15: Fiscal 2023 M&A | Immunetrics Acquisition and Integration

    Slide 15: Fiscal 2023 M&A | Immunetrics Acquisition and Integration

    Fiscal 2023 M&A | Immunetrics Acquisition and Integration Integration and consolidation efficiencies ▪ QSP is a critical and growing field ▪ Immunetrics has increased the range of therapeutic areas addressed by our QSP software and services offerings by more than 50% ▪ Ideal fit as the business leve

  16. Slide 16: Fiscal 2023 ESG Achievements

    Slide 16: Fiscal 2023 ESG Achievements

    Fiscal 2023 ESG Achievements Strategic priorities that align with our mission and values and the four pillars of sustainability ENVIRONMENT SOCIAL HUMAN CAPITAL GOVERNANCE Reduced footprint of US-based Updated company privacy policy and Established a paid parental leave Engaged a third-party consult

  17. Slide 17: Attractive Financial Profile

    Slide 17: Attractive Financial Profile

    Attractive Financial Profile Delivering Double-Digit Revenue Growth / Industry Leading Margins​ + Double digit revenue growth​ Strong recurring revenue FY18 FY19 FY20 FY21 FY22 FY23 5 Yr CAGR + supported by a 90%+ Software REVENUE Fee Renewal Rate​ $29.7 $34.0 $41.6 $46.4 $53.9 $59.6 14.9% $ in mill

  18. Slide 18: Fiscal 2024 Guidance

    Slide 18: Fiscal 2024 Guidance

    Fiscal 2024 Guidance Guidance Total Revenue $66M to $69M Total Revenue Growth 10% to 15% Software Revenue Mix 55% to 60% Services Revenue Mix 40% to 45% Diluted EPS $0.66 to $0.68 18

  19. Slide 19: Seasoned Management Team and Scientific Leadership

    Slide 19: Seasoned Management Team and Scientific Leadership

    Seasoned Management Team and Scientific Leadership Highly experienced management team with deep life science industry expertise, track record of growth and strong returns Shawn O’Connor Will Frederick Josh Fohey Chief Executive Officer Chief Financial Officer Vice President, Business Development Bre

  20. Slide 20: Organizational Structure Aligned to Support Customers

    Slide 20: Organizational Structure Aligned to Support Customers

    Organizational Structure Aligned to Support Customers CEO & President Business Units Shared Services Clinical Pharmacology & Physiologically Based Pharmacometrics (CPP) Pharmacokinetics (PBPK) Chief Revenue Officer Chief Financial Officer Quantitative Systems Sales G&A Cheminformatics Pharmacology (

  21. Slide 21: Conclusion

    Slide 21: Conclusion

    Conclusion CONTINUED LEADERSHIP POSITION IN BIOSIMULATION MARKET Delivering on our Enhancing our client facing commitment to scientific Challenges being addressed Focus on Capital Allocation capabilities leadership • Internal R&D investment • Growth and maturity of • Software renewal timing • ASR pr

  22. Slide 22: Appendix

    Slide 22: Appendix

    Appendix

  23. Slide 23: Non-GAAP Definitions

    Slide 23: Non-GAAP Definitions

    Non-GAAP Definitions Adjusted EBITDA Adjusted EBITDA is defined as earnings (loss) before interest, taxes, depreciation and amortization, stock-based compensation, (gain) loss on currency exchange, any acquisition- or financial-transaction-related expenses, and any asset impairment charges. Currency

  24. Slide 24: Cheminformatics and PBPK Solutions

    Slide 24: Cheminformatics and PBPK Solutions

    Cheminformatics and PBPK Solutions LEAD SELECTION PHARMACOLOGY SERVICES TREATMENT REGIMEN PBPK / PBBM Preclinical Regulatory SAFETY Consulting CLINICAL EFFICACY ADMET DMPK 24

  25. Slide 25: Quantitative Systems Pharmacology Solutions

    Slide 25: Quantitative Systems Pharmacology Solutions

    Quantitative Systems Pharmacology Solutions LEAD SELECTION PHARMACOLOGY SERVICES TREATMENT REGIMEN QSP Consulting QST Consulting SAFETY CLINICAL EFFICACY ADMET DMPK 25

  26. Slide 26: Clinical Pharmacology & Pharmacometrics Solutions

    Slide 26: Clinical Pharmacology & Pharmacometrics Solutions

    Clinical Pharmacology & Pharmacometrics Solutions​ LEAD SELECTION PHARMACOLOGY SERVICES TREATMENT REGIMEN Pharmacometrics​ Clinical Pharmacology​ SAFETY Clinical Regulatory Consulting​ CLINICAL EFFICACY ADMET DMPK 26

  27. Slide 27: Services Overview

    Slide 27: Services Overview

    Services Overview + Provides customers with specialized knowledge and expertise​​ + Delivers complementary capabilities to software application solutions​​ + Helps clients minimize or eliminate questions posed by regulatory reviews while decreasing cost and time to develop detailed reports + Drives

  28. Slide 28: Workplace Recognition Awards

    Slide 28: Workplace Recognition Awards

    Workplace Recognition Awards 28

  29. Slide 29: SimulationsPlus

    Slide 29: SimulationsPlus

    iS|+ SimulationsPlus

Source: Internet Archive copy of simulations-plus.com

More decks from Simulations Plus, Inc.

All 167 Simulations Plus decks